Hepion Pharmaceuticals 10/14/2026 Earnings Report

Hepion Pharmaceuticals EPS Results

• Actual EPS: N/A
• Consensus EPS: -$200.00
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Hepion Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Hepion Pharmaceuticals Announcement Details

• Date: 10/14/2026
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Hepion Pharmaceuticals (NASDAQ:HEPA) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for chronic liver diseases. The company harnesses epigenetic and autophagy‐modulating approaches to address high unmet medical needs in conditions such as nonalcoholic steatohepatitis (NASH), fibrosis and hepatocellular carcinoma. Hepion’s research platform is designed to identify and advance small molecules that can halt or reverse liver damage by targeting key pathways involved in inflammation, cellular stress and tissue remodeling.

The company’s lead therapeutic candidate, CRV431, is a cyclophilin inhibitor being evaluated in Phase 2 clinical trials for the treatment of NASH with bridging fibrosis. CRV431 has demonstrated the potential to reduce inflammation, fibrosis and lipid accumulation in preclinical models. In addition to CRV431, Hepion’s pipeline includes early‐stage compounds aimed at inhibiting VPS34, an enzyme involved in autophagy, which may offer complementary mechanisms to improve liver function and slow disease progression. Hepion collaborates with academic institutions and contract research organizations to advance its programs from preclinical development into human studies.

Hepion Pharmaceuticals is headquartered in the United States and conducts multi‐center trials across North America and Europe. The company is led by a management team with extensive experience in pharmaceutical development, regulatory strategy and commercialization. Hepion seeks to leverage its scientific expertise and strategic partnerships to deliver safe and effective therapies for patients suffering from chronic liver disorders.